<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761358</url>
  </required_header>
  <id_info>
    <org_study_id>99010301</org_study_id>
    <nct_id>NCT00761358</nct_id>
  </id_info>
  <brief_title>To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia</brief_title>
  <official_title>To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the superior efficacy of Z-338 to placebo in subjects
      with Functional Dyspepsia, focusing on the assessment of subjective symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General impression at last visit in treatment period</measure>
    <time_frame>4 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate of post-prandial fullness, upper abdominal bloating and early satiety at last visit in treatment period</measure>
    <time_frame>4 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual symptom score</measure>
    <time_frame>Every week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-NDI</measure>
    <time_frame>At 0, 4 week and 4 week after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Impression</measure>
    <time_frame>Every week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>At 0, 4 week and 4 week after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>4 week treatment period and 4 week after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Z-338</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-338</intervention_name>
    <description>Oral</description>
    <arm_group_label>Z-338</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects showing at least one of the 4 symptoms (upper abdominal pain, upper abdominal
             discomfort, epigastric pain, epigastric burning) for at least 6 months before
             obtaining informed consent

          -  Subjects showing two or more of the following symptoms: upper abdominal pain, upper
             abdominal discomfort, post-prandial fullness, upper abdominal bloating, early satiety,
             nausea, vomiting and/or excessive belching for at least 3 months (one of them should
             be post-prandial fullness or early satiation)

          -  Bothersome symptoms should be post-prandial fullness, upper abdominal bloating or
             early satiety at the time of obtaining informed consent

        Exclusion Criteria:

          -  Subjects with structural disease that is likely to explain the symptom (e.g., GERD,
             erosion, ulcer, hiatal hernia, bleeding, malignancy or Barrett's esophagus) confirmed
             by upper endoscopy at the obtaining informed consent

          -  Subjects have heartburn in last 12 weeks before obtaining informed consent

          -  Subjects with irritable bowel disease (IBS)

          -  Subjects with diabetes mellitus requiring treatment

          -  Subjects with serious anxiety disorder

          -  Subjects with depression and/or sleep disorder

          -  Subjects with biliary tract disease and/or pancreatitis (including chronic
             pancreatitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michio Hongo, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Tohoku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>November 21, 2010</last_update_submitted>
  <last_update_submitted_qc>November 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <keyword>Acotiamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

